Delos leads Allecra Therapeutics' €22m round

Existing investors Forbion Capital Partners, Edmond de Rothschild Investment Partners, EMBL Ventures and Allecra's co-founder Nicholas Benedict also participated.

The proceeds will fund phase-2 development of its antibiotic combination designed to treat drug-resistant bacterial infections.

Delos is a healthcare-focused fund that invests in therapeutics and medical technology companies, mostly in China and the US.

Forbion deployed capital from both its main fund and its latest co-investment fund. The main fund closed in April this year on €183m, below its €200m target, while Forbion's co-investment vehicle FCF II Co-invest Fund I held its final close on €75m in September 2015.

Company
Founded in 2013 and based in Weil am Rhein and Saint Louis, Allecra is a biopharmaceutical company focused on the development of treatments to combat multi drug-resistant Gram-negative bacterial infections.

Allecra's wholly owned French subsidiary is a beneficiary of financial support from the French public bank BPI France and from the Région Alsace.

People
Allecra Therapeutics – Nicholas Benedict (CEO).
Forbion Capital Partners – Holger Reithinger (general partner).
Delos Capital – Henry Chen (managing partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• France
• Healthcare
• Germany
• France
• Venture